Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study Assessing Efficacy and Safety of BI 54903 Administered as Very Low Dose Twice Daily or Low Dose Once Daily in the Evning Only Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone.

Next Previous
X
Search
Trial Profile

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study Assessing Efficacy and Safety of BI 54903 Administered as Very Low Dose Twice Daily or Low Dose Once Daily in the Evning Only Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 54903 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Nov 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 28 Oct 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top